Dr Reddy's plans to launch biosimilars in developed markets Hindu Business Line At present, the biosimilar portfolio of the Hyderabad-based company comprises Filgrastim, peg-filgrastim, Rituximab and Darbepoetin alfa. Dr Reddy's global biosimilars business earned $26 million revenue during 2011-12 marking a 25 per cent year-on ... |
